PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), today announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest’s US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control tests and will accelerate its growth and market share worldwide.

Written by

Investors

Verve Event Zurich Investors

Our sophisticated investors include visionary family offices, leading wealth managers, institutions, founders, and senior executives. These individuals and organizations are all committed to shaping the next generation of innovation.

Learn more

Privacy Preference Center